United States Biotechnology & Medical Research

Bio-Techne Corp (TECH)

Track

Over the last 90 days, Bio-Techne Corp has seen a net insider selling of $320,386.08. There were 2 sell transactions and 0 buy transactions. Notably, Director Joshua Molho and Herr Amy E. made significant sales in May 2026. The company's stock has experienced a 2.9% decrease in the past 90 days.
Stock chart
Ticker: TECH Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Herr Amy E.
1 sale — total 320,386 USD
Sale 8 May 2026
Value US$3,566,371.04 | Price 62.17 | Shares 13,441
Proposed sale 8 May 2026
Value US$3,652,311.99 | Price 183.33 | Shares 70,690
Sale 17 Feb 2026
Value US$116,791.48 | Price 59.11 | Shares 1,976
Proposed sale 17 Feb 2026
Value US$116,791.48 | Price 59.11 | Shares 1,976
Sale 25 Aug 2025
Value US$960,388.03 | Price 56.36 | Shares 17,040
Sale 25 Aug 2025
Value US$957,818.40 | Price 56.21 | Shares 17,040
Proposed sale 25 Aug 2025
Value US$960,388.03 | Price 56.36 | Shares 17,040
Proposed sale 25 Aug 2025
Value US$957,849.07 | Price 56.21 | Shares 17,040
Sale 9 Jun 2025
Value US$63,704.83 | Price 49.77 | Shares 1,280
Proposed sale 9 Jun 2025
Value US$63,704.83 | Price 49.77 | Shares 1,280
Sale 14 Feb 2025
Value US$122,690.62 | Price 65.96 | Shares 1,860
Proposed sale 14 Feb 2025
Value US$122,690.62 | Price 65.96 | Shares 1,860
Sale 27 Jan 2025
Value US$129,479.93 | Price 77.95 | Shares 1,661
Sale 27 Jan 2025
Value US$905,533.49 | Price 77.19 | Shares 11,731
Proposed sale 27 Jan 2025
Value US$1,031,853.60 | Price 77.05 | Shares 13,392
Sale 8 Aug 2024
Value US$1,153,664.00 | Price 72.10 | Shares 16,000
Proposed sale 8 Aug 2024
Value US$1,153,664.00 | Price 72.10 | Shares 16,000
Sale 14 May 2024
Value US$335,377.20 | Price 83.84 | Shares 4,000
Proposed sale 14 May 2024
Value US$335,377.20 | Price 83.84 | Shares 4,000
Sale 7 Mar 2024
Value US$800,627.36 | Price 76.98 | Shares 10,400
Proposed sale 7 Mar 2024
Value US$800,626.00 | Price 76.98 | Shares 10,400
Sale 30 Aug 2023
Value US$717,959.03 | Price 80.32 | Shares 8,939
Proposed sale 30 Aug 2023
Value US$717,959.03 | Price 80.32 | Shares 8,939
Planned sale 21 Jul 2023
Value US$7,069,024.00 | Price 88.36 | Shares 80,000
Proposed sale 21 Jul 2023
Value US$7,069,024.00 | Price 88.36 | Shares 80,000
Sale 7 Jun 2023
Value US$26,726.00 | Price 83.00 | Shares 322
Proposed sale 6 Jun 2023
Value US$4,150,000.00 | Price 83.00 | Shares 50,000
Sale 8 Dec 2022
Value US$611,810.39 | Price 82.12 | Shares 7,450
Sale 7 Dec 2022
Value US$65,605.04 | Price 82.01 | Shares 800
Sale 11 Aug 2022
Value US$3,045.68 | Price 380.71 | Shares 8
Sale 11 Aug 2022
Value US$194,276.58 | Price 385.47 | Shares 504
Sale 10 Aug 2022
Value US$377,111.78 | Price 380.15 | Shares 992
Sale 10 Aug 2022
Value US$37,489.50 | Price 374.90 | Shares 100
Sale 10 Aug 2022
Value US$336,592.62 | Price 373.99 | Shares 900
Sale 8 Jun 2022
Value US$219,654.00 | Price 366.09 | Shares 600
Sale 7 Jun 2022
Value US$1,862,960.00 | Price 365.00 | Shares 5,104
Sale 7 Jun 2022
Value US$364,310.00 | Price 364.31 | Shares 1,000
Buy 10 May 2022
Value US$105,765.00 | Price 352.55 | Shares 300
Sale 19 Nov 2021
Value US$202,313.00 | Price 505.78 | Shares 400
Sale 19 Nov 2021
Value US$50,376.00 | Price 503.76 | Shares 100
Sale 12 Nov 2021
Value US$203,002.20 | Price 506.24 | Shares 401
Sale 12 Nov 2021
Value US$1,281,407.26 | Price 505.49 | Shares 2,535
Sale 12 Nov 2021
Value US$4,533,985.08 | Price 504.39 | Shares 8,989
Sale 12 Nov 2021
Value US$4,554,137.09 | Price 503.61 | Shares 9,043
Sale 12 Nov 2021
Value US$2,038,220.66 | Price 502.77 | Shares 4,054
Sale 12 Nov 2021
Value US$202,002.00 | Price 505.01 | Shares 400
Sale 12 Nov 2021
Value US$270,725.17 | Price 504.14 | Shares 537
Sale 12 Nov 2021
Value US$150,897.00 | Price 502.99 | Shares 300
Sale 12 Nov 2021
Value US$100,956.00 | Price 504.78 | Shares 200
Sale 12 Nov 2021
Value US$352,860.48 | Price 504.09 | Shares 700
Planned sale 2 Nov 2021
Value US$105,020.00 | Price 525.10 | Shares 200
Planned sale 1 Nov 2021
Value US$498,426.80 | Price 528.55 | Shares 943
Planned sale 1 Nov 2021
Value US$755,903.06 | Price 527.50 | Shares 1,433
Planned sale 1 Nov 2021
Value US$1,516,321.44 | Price 526.50 | Shares 2,880
Planned sale 1 Nov 2021
Value US$1,874,318.48 | Price 525.61 | Shares 3,566
Planned sale 29 Oct 2021
Value US$347,704.05 | Price 525.23 | Shares 662
Planned sale 28 Oct 2021
Value US$52,518.00 | Price 525.18 | Shares 100
Sale 31 Aug 2021
Value US$773,727.66 | Price 503.07 | Shares 1,538
Sale 31 Aug 2021
Value US$1,573,010.70 | Price 506.12 | Shares 3,108
Sale 31 Aug 2021
Value US$792,754.82 | Price 505.26 | Shares 1,569
Sale 31 Aug 2021
Value US$162,545.97 | Price 503.24 | Shares 323
Sale 9 Aug 2021
Value US$145,493.76 | Price 484.98 | Shares 300
Sale 9 Aug 2021
Value US$145,085.01 | Price 483.62 | Shares 300
Sale 9 Aug 2021
Value US$144,481.50 | Price 481.61 | Shares 300
Sale 9 Aug 2021
Value US$336,462.49 | Price 480.66 | Shares 700
Sale 9 Aug 2021
Value US$48,070.00 | Price 480.70 | Shares 100
Sale 9 Aug 2021
Value US$623,953.72 | Price 479.96 | Shares 1,300
Sale 9 Aug 2021
Value US$861,444.00 | Price 478.58 | Shares 1,800
Sale 9 Aug 2021
Value US$2,484,001.52 | Price 477.69 | Shares 5,200
Planned sale 18 Jun 2021
Value US$146,820.62 | Price 450.37 | Shares 326
Planned sale 18 Jun 2021
Value US$1,159,999.47 | Price 449.09 | Shares 2,583
Planned sale 17 Jun 2021
Value US$49,282.17 | Price 452.13 | Shares 109
Planned sale 17 Jun 2021
Value US$474,117.00 | Price 451.54 | Shares 1,050
Planned sale 17 Jun 2021
Value US$764,762.22 | Price 450.39 | Shares 1,698
Planned sale 17 Jun 2021
Value US$3,025,024.20 | Price 449.35 | Shares 6,732
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-12 2026-05-08 S Sale
3.2
Herr Amy E.
Non-Executive Director
13,441 +25.1%
62.17
US$3,566,371 		13,441 +25.1% 62.17 US$3,566,371
2026-05-08 2026-05-08 PrS Proposed sale
3.2
JOSHUA MOLHO

Director

Non-Executive Director
70,690
183.33
US$3,652,312 		70,690 183.33 US$3,652,312
2026-02-19 2026-02-17 S Sale
3.2
Herr Amy E.
Non-Executive Director
50,417 -6.3%
172.89
US$3,297,005 		50,417 -6.3% 172.89 US$3,297,005
2026-02-17 2026-02-17 PrS Proposed sale
3.2
JOSHUA MOLHO

Director

Non-Executive Director
1,976
59.11
US$116,791 		1,976 59.11 US$116,791
2025-08-27 2025-08-25 S Sale
3.0
Nusse Roeland
Non-Executive Director
17,040 -27.7%
56.36
US$960,388 		17,040 -27.7% 56.36 US$960,388
2025-08-27 2025-08-25 S Sale
1.7
BAUMGARTNER ROBERT V
Non-Executive Director
17,040 -27.5%
56.21
US$957,818 		17,040 -27.5% 56.21 US$957,818
2025-08-25 2025-08-25 PrS Proposed sale
3.0
ROELAND NUSSE

Director

Non-Executive Director
17,040
56.36
US$960,388 		17,040 56.36 US$960,388
2025-08-25 2025-08-25 PrS Proposed sale
1.7
ROBERT V. BAUMGARTNER4731 BONITA BAY BOULEVARD

Director

Non-Executive Director
17,040
56.21
US$957,849 		17,040 56.21 US$957,849
2025-06-11 2025-06-09 S Sale
3.2
Herr Amy E.
Non-Executive Director
1,280 -39.3%
49.77
US$63,705 		1,280 -39.3% 49.77 US$63,705
2025-06-09 2025-06-09 PrS Proposed sale
3.2
JOSHUA MOLHO

Officer

Officer
1,280
49.77
US$63,705 		1,280 49.77 US$63,705
2025-02-18 2025-02-14 S Sale
3.2
Herr Amy E.
Non-Executive Director
1,860 -48.5%
65.96
US$122,691 		1,860 -48.5% 65.96 US$122,691
2025-02-14 2025-02-14 PrS Proposed sale
3.2
JOSHUA MOLHO

Domestic Partner of Director

Non-Executive Director
1,860
65.96
US$122,691 		1,860 65.96 US$122,691
2025-01-29 2025-01-27 S Sale
3.7
Kelderman Kim

Chief Executive Officer

Executive Director
1,661 -4.1%
77.95
US$129,480 		1,661 -4.1% 77.95 US$129,480
2025-01-29 2025-01-27 S Sale
3.7
Kelderman Kim

Chief Executive Officer

Executive Director
11,731 -22.4%
77.19
US$905,533 		11,731 -22.4% 77.19 US$905,533
2025-01-27 2025-01-27 PrS Proposed sale
3.7
KIM KELDERMAN

Director; Officer

Executive Director
13,392
77.05
US$1,031,854 		13,392 77.05 US$1,031,854
2024-08-12 2024-08-08 S Sale
1.7
BAUMGARTNER ROBERT V
Non-Executive Director
16,000 -26.9%
72.10
US$1,153,664 		16,000 -26.9% 72.10 US$1,153,664
2024-08-08 2024-08-08 PrS Proposed sale
1.7
ROBERT V. BAUMGARTNER

Director

Non-Executive Director
16,000
72.10
US$1,153,664 		16,000 72.10 US$1,153,664
2024-05-16 2024-05-14 S Sale
3.4
HIGGINS JOHN L
Non-Executive Director
4,000 -9.9%
83.84
US$335,377 		4,000 -9.9% 83.84 US$335,377
2024-05-14 2024-05-14 PrS Proposed sale
3.4
JOHN L HIGGINS

Director

Non-Executive Director
4,000
83.84
US$335,377 		4,000 83.84 US$335,377
2024-03-11 2024-03-07 S Sale
3.0
Nusse Roeland
Non-Executive Director
10,400 -19.4%
76.98
US$800,627 		10,400 -19.4% 76.98 US$800,627
2024-03-07 2024-03-07 PrS Proposed sale
3.0
Nusse Roeland

Director

Non-Executive Director
10,400
76.98
US$800,626 		10,400 76.98 US$800,626
2023-09-01 2023-08-30 S Sale
3.0
Nusse Roeland
Non-Executive Director
8,939 -14.7%
80.32
US$717,959 		8,939 -14.7% 80.32 US$717,959
2023-08-30 2023-08-30 PrS Proposed sale
3.0
ROELAND NUSSE

Director

Non-Executive Director
8,939
80.32
US$717,959 		8,939 80.32 US$717,959
2023-07-25 2023-07-21 PlS Planned sale
2.8
Kummeth Charles R.

Chief Executive Officer

Executive Director
80,000 -6.0%
88.36
US$7,069,024 		80,000 -6.0% 88.36 US$7,069,024
2023-07-21 2023-07-21 PrS Proposed sale
2.8
Kummeth Charles R.

Officer

Officer
80,000
88.36
US$7,069,024 		80,000 88.36 US$7,069,024
2023-06-09 2023-06-07 S Sale
2.8
Kummeth Charles R.

Chief Executive Officer

Executive Director
322 -0.0%
83.00
US$26,726 		322 -0.0% 83.00 US$26,726
2023-06-06 2023-06-06 PrS Proposed sale
2.8
Charles Kummeth

Officer

Officer
50,000
83.00
US$4,150,000 		50,000 83.00 US$4,150,000
2022-12-09 2022-12-08 S Sale
2.8
Furlow Brenda S.

SVP - GENERAL COUNSEL

Officer
7,450 -22.2%
82.12
US$611,810 		7,450 -22.2% 82.12 US$611,810
2022-12-09 2022-12-07 S Sale
2.8
Furlow Brenda S.

SVP - GENERAL COUNSEL

Officer
800 -3.0%
82.01
US$65,605 		800 -3.0% 82.01 US$65,605
2022-08-12 2022-08-11 S Sale
3.4
HIGGINS JOHN L
Non-Executive Director
8 -0.1%
380.71
US$3,046 		8 -0.1% 380.71 US$3,046
2022-08-12 2022-08-11 S Sale
3.4
HIGGINS JOHN L
Non-Executive Director
504 -8.4%
385.47
US$194,277 		504 -8.4% 385.47 US$194,277
2022-08-12 2022-08-10 S Sale
3.4
HIGGINS JOHN L
Non-Executive Director
992 -14.2%
380.15
US$377,112 		992 -14.2% 380.15 US$377,112
2022-08-12 2022-08-10 S Sale
3.4
HIGGINS JOHN L
Non-Executive Director
100 -1.4%
374.90
US$37,490 		100 -1.4% 374.90 US$37,490
2022-08-12 2022-08-10 S Sale
3.4
HIGGINS JOHN L
Non-Executive Director
900 -11.2%
373.99
US$336,593 		900 -11.2% 373.99 US$336,593
2022-06-09 2022-06-08 S Sale
3.4
HIGGINS JOHN L
Non-Executive Director
600 -11.5%
366.09
US$219,654 		600 -11.5% 366.09 US$219,654
2022-06-09 2022-06-07 S Sale
2.8
Kummeth Charles R.

CHIEF EXECUTIVE OFFICER

Executive Director
5,104 -2.5%
365.00
US$1,862,960 		5,104 -2.5% 365.00 US$1,862,960
2022-06-09 2022-06-07 S Sale
3.4
HIGGINS JOHN L
Non-Executive Director
1,000 -17.8%
364.31
US$364,310 		1,000 -17.8% 364.31 US$364,310
2022-05-11 2022-05-10 B Purchase
1.7
BAUMGARTNER ROBERT V
Non-Executive Director
300 +3.1%
352.55
US$105,765 		300 +3.1% 352.55 US$105,765
2021-11-23 2021-11-19 S Sale
3.7
Kelderman Kim

Pres. Diagnostics & Genom

Officer
400 -100.0%
505.78
US$202,313 		400 -100.0% 505.78 US$202,313
2021-11-23 2021-11-19 S Sale
3.7
Kelderman Kim

Pres. Diagnostics & Genom

Officer
100 -20.0%
503.76
US$50,376 		100 -20.0% 503.76 US$50,376
2021-11-16 2021-11-12 S Sale
3.6
Eansor Norman David

President-Protein Sciences

Officer
401 -23.3%
506.24
US$203,002 		401 -23.3% 506.24 US$203,002
2021-11-16 2021-11-12 S Sale
3.6
Eansor Norman David

President-Protein Sciences

Officer
2,535 -59.6%
505.49
US$1,281,407 		2,535 -59.6% 505.49 US$1,281,407
2021-11-16 2021-11-12 S Sale
3.6
Eansor Norman David

President-Protein Sciences

Officer
8,989 -67.9%
504.39
US$4,533,985 		8,989 -67.9% 504.39 US$4,533,985
2021-11-16 2021-11-12 S Sale
3.6
Eansor Norman David

President-Protein Sciences

Officer
9,043 -40.6%
503.61
US$4,554,137 		9,043 -40.6% 503.61 US$4,554,137
2021-11-16 2021-11-12 S Sale
3.6
Eansor Norman David

President-Protein Sciences

Officer
4,054 -15.4%
502.77
US$2,038,221 		4,054 -15.4% 502.77 US$2,038,221
2021-11-16 2021-11-12 S Sale
3.6
Eansor Norman David

President-Protein Sciences

Officer
400 -1.5%
505.01
US$202,002 		400 -1.5% 505.01 US$202,002
2021-11-16 2021-11-12 S Sale
3.6
Eansor Norman David

President-Protein Sciences

Officer
537 -2.0%
504.14
US$270,725 		537 -2.0% 504.14 US$270,725
2021-11-16 2021-11-12 S Sale
3.6
Eansor Norman David

President-Protein Sciences

Officer
300 -1.1%
502.99
US$150,897 		300 -1.1% 502.99 US$150,897
2021-11-16 2021-11-12 S Sale
3.6
Eansor Norman David

President-Protein Sciences

Officer
200 -0.7%
504.78
US$100,956 		200 -0.7% 504.78 US$100,956
2021-11-16 2021-11-12 S Sale
3.6
Eansor Norman David

President-Protein Sciences

Officer
700 -2.5%
504.09
US$352,860 		700 -2.5% 504.09 US$352,860
2021-11-03 2021-11-02 PlS Planned sale
2.4
Hippel James

Chief Financial Officer

Officer
200 -1.8%
525.10
US$105,020 		200 -1.8% 525.10 US$105,020
2021-11-03 2021-11-01 PlS Planned sale
2.4
Hippel James

Chief Financial Officer

Officer
943 -8.1%
528.55
US$498,427 		943 -8.1% 528.55 US$498,427
2021-11-03 2021-11-01 PlS Planned sale
2.4
Hippel James

Chief Financial Officer

Officer
1,433 -10.9%
527.50
US$755,903 		1,433 -10.9% 527.50 US$755,903
2021-11-03 2021-11-01 PlS Planned sale
2.4
Hippel James

Chief Financial Officer

Officer
2,880 -18.0%
526.50
US$1,516,321 		2,880 -18.0% 526.50 US$1,516,321
2021-11-03 2021-11-01 PlS Planned sale
2.4
Hippel James

Chief Financial Officer

Officer
3,566 -18.2%
525.61
US$1,874,318 		3,566 -18.2% 525.61 US$1,874,318
2021-11-01 2021-10-29 PlS Planned sale
2.4
Hippel James

Chief Financial Officer

Officer
662 -5.8%
525.23
US$347,704 		662 -5.8% 525.23 US$347,704
2021-11-01 2021-10-28 PlS Planned sale
2.4
Hippel James

Chief Financial Officer

Officer
100 -0.9%
525.18
US$52,518 		100 -0.9% 525.18 US$52,518
2021-09-02 2021-08-31 S Sale
3.6
Eansor Norman David

President-Protein Sciences

Officer
1,538 -53.9%
503.07
US$773,728 		1,538 -53.9% 503.07 US$773,728
2021-09-02 2021-08-31 S Sale
2.8
Furlow Brenda S.

SVP - General Counsel

Officer
3,108 -29.0%
506.12
US$1,573,011 		3,108 -29.0% 506.12 US$1,573,011
2021-09-02 2021-08-31 S Sale
2.8
Furlow Brenda S.

SVP - General Counsel

Officer
1,569 -12.8%
505.26
US$792,755 		1,569 -12.8% 505.26 US$792,755
2021-09-02 2021-08-31 S Sale
2.8
Furlow Brenda S.

SVP - General Counsel

Officer
323 -2.6%
503.24
US$162,546 		323 -2.6% 503.24 US$162,546
2021-08-10 2021-08-09 S Sale
2.4
Hippel James

Chief Financial Officer

Officer
300 -2.7%
484.98
US$145,494 		300 -2.7% 484.98 US$145,494
2021-08-10 2021-08-09 S Sale
2.4
Hippel James

Chief Financial Officer

Officer
300 -2.6%
483.62
US$145,085 		300 -2.6% 483.62 US$145,085
2021-08-10 2021-08-09 S Sale
2.4
Hippel James

Chief Financial Officer

Officer
300 -2.6%
481.61
US$144,482 		300 -2.6% 481.61 US$144,482
2021-08-10 2021-08-09 S Sale
2.4
Hippel James

Chief Financial Officer

Officer
700 -5.6%
480.66
US$336,462 		700 -5.6% 480.66 US$336,462
2021-08-10 2021-08-09 S Sale
2.4
Hippel James

Chief Financial Officer

Officer
100 -0.8%
480.70
US$48,070 		100 -0.8% 480.70 US$48,070
2021-08-10 2021-08-09 S Sale
2.4
Hippel James

Chief Financial Officer

Officer
1,300 -9.4%
479.96
US$623,954 		1,300 -9.4% 479.96 US$623,954
2021-08-10 2021-08-09 S Sale
2.4
Hippel James

Chief Financial Officer

Officer
1,800 -11.5%
478.58
US$861,444 		1,800 -11.5% 478.58 US$861,444
2021-08-10 2021-08-09 S Sale
2.4
Hippel James

Chief Financial Officer

Officer
5,200 -24.9%
477.69
US$2,484,002 		5,200 -24.9% 477.69 US$2,484,002
2021-06-21 2021-06-18 PlS Planned sale
2.8
Kummeth Charles R.

Chief Executive Officer

Executive Director
326 -0.2%
450.37
US$146,821 		326 -0.2% 450.37 US$146,821
2021-06-21 2021-06-18 PlS Planned sale
2.8
Kummeth Charles R.

Chief Executive Officer

Executive Director
2,583 -1.6%
449.09
US$1,159,999 		2,583 -1.6% 449.09 US$1,159,999
2021-06-21 2021-06-17 PlS Planned sale
2.8
Kummeth Charles R.

Chief Executive Officer

Executive Director
109 -0.1%
452.13
US$49,282 		109 -0.1% 452.13 US$49,282
2021-06-21 2021-06-17 PlS Planned sale
2.8
Kummeth Charles R.

Chief Executive Officer

Executive Director
1,050 -0.7%
451.54
US$474,117 		1,050 -0.7% 451.54 US$474,117
2021-06-21 2021-06-17 PlS Planned sale
2.8
Kummeth Charles R.

Chief Executive Officer

Executive Director
1,698 -1.1%
450.39
US$764,762 		1,698 -1.1% 450.39 US$764,762
2021-06-21 2021-06-17 PlS Planned sale
2.8
Kummeth Charles R.

Chief Executive Officer

Executive Director
6,732 -4.0%
449.35
US$3,025,024 		6,732 -4.0% 449.35 US$3,025,024
Explore more

More insider trading research around Bio-Techne Corp

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America